1105 related articles for article (PubMed ID: 16525645)
1. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
2. Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice.
Nagai E; Ogawa T; Kielian T; Ikubo A; Suzuki T
Cancer Immunol Immunother; 1998 Oct; 47(2):72-80. PubMed ID: 9769115
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cells.
Shinagawa N; Yamazaki K; Tamura Y; Imai A; Kikuchi E; Yokouchi H; Hommura F; Oizumi S; Nishimura M
Cancer Immunol Immunother; 2008 Feb; 57(2):165-74. PubMed ID: 17628800
[TBL] [Abstract][Full Text] [Related]
4. Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor.
Wang XY; Li Y; Manjili MH; Repasky EA; Pardoll DM; Subjeck JR
Cancer Immunol Immunother; 2002 Aug; 51(6):311-9. PubMed ID: 12111119
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activation of cytotoxic T lymphocytes by fusion of mouse hepatocellular carcinoma cells and lymphotactin gene-modified dendritic cells.
Sheng XL; Zhang H
World J Gastroenterol; 2007 Nov; 13(44):5944-50. PubMed ID: 17990361
[TBL] [Abstract][Full Text] [Related]
6. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
7. Immunostimulatory properties of human dendritic cells generated using IFN-beta associated either with IL-3 or GM-CSF.
Mazouz N; Detournay O; Buelens C; Renneson J; Trakatelli M; Lambermont M; Goldman M; Toungouz M
Cancer Immunol Immunother; 2005 Oct; 54(10):1010-7. PubMed ID: 15864589
[TBL] [Abstract][Full Text] [Related]
8. Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells.
Li HS; Liu C; Xiao Y; Chu F; Liang X; Peng W; Hu J; Neelapu SS; Sun SC; Hwu P; Watowich SS
Sci Signal; 2016 Sep; 9(447):ra94. PubMed ID: 27678219
[TBL] [Abstract][Full Text] [Related]
9. Transgene IL-6 enhances DC-stimulated CTL responses by counteracting CD4+25+Foxp3+ regulatory T cell suppression via IL-6-induced Foxp3 downregulation.
Bhanumathy KK; Zhang B; Ahmed KA; Qureshi M; Xie Y; Tao M; Tan X; Xiang J
Int J Mol Sci; 2014 Mar; 15(4):5508-21. PubMed ID: 24690994
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity.
Yamaguchi S; Tatsumi T; Takehara T; Sasakawa A; Hikita H; Kohga K; Uemura A; Sakamori R; Ohkawa K; Hayashi N
Cancer Immunol Immunother; 2008 Dec; 57(12):1861-9. PubMed ID: 18438665
[TBL] [Abstract][Full Text] [Related]
11. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.
Yasuda T; Kamigaki T; Kawasaki K; Nakamura T; Yamamoto M; Kanemitsu K; Takase S; Kuroda D; Kim Y; Ajiki T; Kuroda Y
Cancer Immunol Immunother; 2007 Jul; 56(7):1025-36. PubMed ID: 17131118
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen.
Hess PR; Boczkowski D; Nair SK; Snyder D; Gilboa E
Cancer Immunol Immunother; 2006 Jun; 55(6):672-83. PubMed ID: 16133108
[TBL] [Abstract][Full Text] [Related]
13. Mature dendritic cells differentiated in the presence of interferon-beta and interleukin-3 prime functional antigen-specific CD8 T cells.
Renneson J; Salio M; Mazouz N; Goldman M; Marchant A; Cerundolo V
Clin Exp Immunol; 2005 Mar; 139(3):468-75. PubMed ID: 15730392
[TBL] [Abstract][Full Text] [Related]
14. Antitumor vaccination effect of dendritic cells can be augmented by locally utilizing Th1-type cytokines from OK432-reactive CD4+ T cells.
Tamada K; Harada M; Abe K; Li T; Tada H; Onoe Y; Nomoto K
Cancer Immunol Immunother; 1998 May; 46(3):128-36. PubMed ID: 9625536
[TBL] [Abstract][Full Text] [Related]
15. Generation of tumor cell lysate-loaded dendritic cells preprogrammed for IL-12 production and augmented T cell response.
Vegh Z; Mazumder A
Cancer Immunol Immunother; 2003 Feb; 52(2):67-79. PubMed ID: 12594570
[TBL] [Abstract][Full Text] [Related]
16. In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery.
Pan PY; Li Y; Li Q; Gu P; Martinet O; Thung S; Chen SH
Cancer Immunol Immunother; 2004 Jan; 53(1):17-25. PubMed ID: 12955480
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1alpha and accumulation of dendritic cells at vaccination sites in vivo.
Kielian T; Nagai E; Ikubo A; Rasmussen CA; Suzuki T
Cancer Immunol Immunother; 1999; 48(2-3):123-31. PubMed ID: 10414466
[TBL] [Abstract][Full Text] [Related]
18. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
Kowalczyk A; Wierzbicki A; Gil M; Bambach B; Kaneko Y; Rokita H; Repasky E; Fenstermaker R; Brecher M; Ciesielski M; Kozbor D
Cancer Immunol Immunother; 2007 Sep; 56(9):1443-58. PubMed ID: 17597331
[TBL] [Abstract][Full Text] [Related]
19. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity.
Yi H; Guo C; Yu X; Gao P; Qian J; Zuo D; Manjili MH; Fisher PB; Subjeck JR; Wang XY
Cancer Res; 2011 Nov; 71(21):6611-20. PubMed ID: 21914786
[TBL] [Abstract][Full Text] [Related]
20. Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA.
Teramoto K; Kontani K; Fujita T; Ozaki Y; Sawai S; Tezuka N; Fujino S; Itoh Y; Taguchi O; Kannagi R; Ogasawara K
Cancer Immunol Immunother; 2007 Mar; 56(3):331-42. PubMed ID: 16896967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]